Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005659700
Thu, 08.06.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Würzburg, Bavaria, 8 June 2023. PentixaPharm GmbH, a developer of innovative radiopharmaceuticals fully owned by Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700; TecDax) has received the approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to start PTT101, its open-label dose escalation study to e [ … ]
Wed, 07.06.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 7 June 2023. At today's Annual General Meeting of Eckert & Ziegler AG, the shareholders approved the proposal of the Executive Board and Supervisory Board to distribute a dividend of 0.50 EUR per dividend-bearing share. All items on the agenda were accepted by the shareholders. A total of 57.75% of the share capital of Eckert & Zieg [ … ]
Wed, 07.06.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 7 June 2023. At today's Annual General Meeting of Eckert & Ziegler AG, the shareholders approved the proposal of the Executive Board and Supervisory Board to distribute a dividend of 0.50 EUR per dividend-bearing share. All items on the agenda were accepted by the shareholders. A total of 57.75% of the share capital of Eckert & Zieg [ … ]
Tue, 30.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
BOSTON, Mass., May 30, 2023 – By organizing the first Boston Radionuclide Theranostics Forum and bringing together numerous renowned experts in Boston, Mass., Eckert & Ziegler underscores its leading position in the field of radiopharmaceuticals. On June 1st, 2023, the company will connect potential and existing partners as well as key industry [ … ]
Tue, 30.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
BOSTON, Mass., May 30, 2023 – By organizing the first Boston Radionuclide Theranostics Forum and bringing together numerous renowned experts in Boston, Mass., Eckert & Ziegler underscores its leading position in the field of radiopharmaceuticals. On June 1st, 2023, the company will connect potential and existing partners as well as key industry [ … ]
Mon, 15.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, May 15, 2023. The Supervisory Board of Eckert & Ziegler AG has now formally approved the reorganization of the Executive Board already announced in December 2022. Accordingly, the founder and Chairman of the Executive Board, Dr. Andreas Eckert, and the Chief Operating Officer of the Medical segment, Dr. Lutz Helmke, will resign from the [ … ]
Mon, 15.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, May 15, 2023. The Supervisory Board of Eckert & Ziegler AG has now formally approved the reorganization of the Executive Board already announced in December 2022. Accordingly, the founder and Chairman of the Executive Board, Dr. Andreas Eckert, and the Chief Operating Officer of the Medical segment, Dr. Lutz Helmke, will resign from the [ … ]
Thu, 11.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 11 May 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 16% to EUR 57.9 million in the first quarter of 2023. Net income amounted to EUR 4.7 million or EUR 0.23 per share and was thus 29% lower than in the same quarter of the previous year, mainly due to currency losses as well as [ … ]
Thu, 11.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 11 May 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 16% to EUR 57.9 million in the first quarter of 2023. Net income amounted to EUR 4.7 million or EUR 0.23 per share and was thus 29% lower than in the same quarter of the previous year, mainly due to currency losses as well as [ … ]
Mon, 08.05.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 8 May 2023 – Following clinical investigations of hypertension specialists in the Netherlands, France, the United States, and China, the Monash Medical Center (Monash Health) and Hudson Institute in Melbourne, Australia, has commenced an investigator initiated clinical study with PentixaPharm’s novel lead compound [68Ga]Ga-PentixaFor target [ … ]